Note: Descriptions are shown in the official language in which they were submitted.
CA 02335293 2000-12-15
WO 99/65495 PCT/US99/13897
INHIBITORS OF TRANSCRIPTION FACTOR NF-xB
FIELD OF THE INVENTION
This invention relates in general to methods of inhibiting transcription
factor NF-
S xB using amino-indanones. Such compounds are particularly useful for
treating diseases in
which activation of NF-xB is implicated. More specifically, these compounds
inhibit IxB
phosphorylation and subsequent degradation. Such compounds are useful in the
treatment
of a variety of diseases associated with NF-xB activation including
inflammatory disorders;
particularly rheumatoid arthritis, inflammatory bowel disease, and asthma;
dermatosis,
including psoriasis and atopic dermatitis; autoimmune diseases: tissue and
organ rejection;
Alzheimer's disease: stroke: atherosclerosis; restenosis; cancer, including
Hodgkins disease;
and certain viral infections, including AIDS; osteoarthritis: osteoporosis:
and Ataxia
Telangiestasia.
IS BACKGROUND OF THE INVENTION
Recent advances in scientific understanding of the mediators involved in acute
and
chronic inflammatory diseases and cancer have led to new strategies in the
search for
effective therapeutics. Traditional approaches include direct target
intervention such as the
use of specific antibodies, receptor antagonists, or enzyme inhibitors. Recent
breakthroughs in the elucidation of regulatory mechanisms involved in the
transcription and
translation of a variety of mediators have led to increased interest in
therapeutic approaches
directed at the level of gene transcription.
NF-xB belongs to a family of closely related dimeric transcription factor
complexes composed of various combinations of the Rel/ NF-xB family of
polypeptides.
2S The family consists of five individual gene products in mammals, ReIA
(p6S), NF-xB 1
(pS0/ plOS), NF-xB2 (p49/ p100), c-Rel, and ReIB, all of which can form hetero-
or
homodimers. These proteins share a highly homologous 300 amino acid "Rel
homology
domain" which contains the DNA binding and dimerization domains. At the
extreme C-
terminus of the Rel homology domain is a nuclear translocation sequence
important in the
transport of NF-xB from the cytoplasm to the nucleus. In addition, p6S and
cRel possess
potent transactivation domains at their C-tetmtinal ends.
CA 02335293 2000-12-15
WO 99/65495 PCT/IJS99/13897
The activity of NF-xB is regulated by its interaction with a member of the
inhibitor
IxB family of proteins. This interaction effectively blocks the nuclear
localization sequence
on the NF-xB proteins, thus preventing migration of the dimer to the nucleus.
A wide
variety of stimuli activate NF-xB through what are likely to be multiple
signal transduction
pathways. Included are bacterial products (LPS), some viruses (HIV-l, HTLV-1),
inflammatory cytokines (TNFx, IL-1), and environmental stress. Apparently
common to
all stimuli however, is the phosphorylation and subsequent degradation of IxB.
IxB is
phosphorylated on two N-terminal serines by the recently identified IxB
kinases (IKK-oc
and IKK-(3). Site-directed mutagenesis studies indicate that these
phosphorylations are
critical for the subsequent activation of NF-xB in that once phosphorylated
the protein is
flagged for degradation via the ubiquitin-proteasome pathway. Free from IxB,
the active
NF-xB complexes are able to translocate to the nucleus where they bind in a
selective
manner to preferred gene-specific enhancer sequences. Included in the genes
regulated by
NF-xB are a number of cytokines, cell adhesion molecules, and acute phase
proteins.
It is well-known that NF-xB plays a key role in the regulated expression of a
large
number of pro-inflammatory mediators including cytokines such as IL-6 and IL-
8, cell
adhesion molecules, such as ICAM and VCAM, and inducible nitric oxide synthase
(iNOS). Such mediators are known to play a role in the recruitment of
leukocytes at sites of
inflammation and in the case of iNOS, may lead to organ destruction in some
inflammatory
and autoimmune diseases.
The importance of NF-xB in inflammatory disorders is further strengthened by
studies of airway inflammation including asthma, in which NF-xB has been shown
to be
activated. This activation may underlie the increased cytokine production and
leukocyte
infiltration characteristic of these disorders. In addition, inhaled steroids
are known to
reduce airway hyperresponsiveness and suppress the inflammatory response in
asthmatic
airways. In Light of the recent findings with regard to glucocorticoid
inhibition of NF-xB,
one may speculate that these effects are mediated through an inhibition of NF-
xB.
Further evidence for a role of NF-xB in inflammatory disorders comes from
studies
of rheumatoid synovium. Although NF-xB is normally present as an inactive
cytoplasmic
complex, recent immunohistochemical studies have indicated that NF-xB is
present in the
nuclei, and hence active, in the cells comprising rheumatoid synovium.
Furthermore, NF-
2
CA 02335293 2000-12-15
- WO 99/65495 PCT/US99/13897
xB has been shown to be activated in human synovial cells in response to
stimulation with
TNF-x. Such a distribution may be the underlying mechanism for the increased
cytokine
and eicosanoid production characteristic of this tissue. See Roshak, A. K., ei
al., J. Biol.
Chem., 271, 31496-31501 ( 1996).
The NF-xB/Rel and IxB proteins are also likely to play a key role in
neoplastic
transformation. Family members are associated with cell transformation in
vitro and in vivo
as a result of overexpression, gene amplification . gene rearrangements or
translocations.
In addition. rearrangement and/or amplification of the genes encoding these
proteins are
seen in 20-25~Ic of certain human lymphoid tumors. In addition, a role for NF-
xB in the
regulation of apoptosis has been reported stregthening the role of this
transcription factor in
the control of cell proliferation.
Several NF-xB inhibitors are described in C. Wahl, et al. J. Clin. Ir:vest.
101(5),
1163-1174 ( 1998): R. W. Sullivan, et al. J. ~Ylecl. Chem. 41, 413-419 (1998);
J. W. Pierce, et
al. J. Biol. Chem. 272, 21096-21103 ( 1997).
The marine natural product hymenialdisine is known to inhibit NF-xB. Roshak.
A.,
et al., JPET, 283, 955-961 ( 1997). Breton, J. J and Chabot-Fletcher, M. C.,
JPET, 282,
459-466 ( 1997).
Amino-indanones are known compounds. General preparation of amino-indanone
analogs was described by G. Maury, E.-M. Wu. N. H. Cromwell, J. Org. Chem.
1968, 33,
1900-1907. The synthesis of the 3-bromo intermediate was described by B. D.
Pearson, R.
P. Ayer, N. H. Cromwell, J. Org. Chem. 1962. ?7. 3038-3044. The synthesis of 2-
benzalindanone was desbribed by A. Hassner. N. H. Cromwell, J. Org. Chem 1958.
80.
893-900.
We have now discovered a novel method of inhibiting the activation of
transcription factor NF-xB using amino-indanones.
SUMMARY OF THE INVENTION
An object of the present invention is to provide a method for treating
diseases
which may be therapeutically modified by altering the activity of
transcription factor NF-
xB.
3
CA 02335293 2000-12-15
WO 99/65495 PCT/US99/13897
Accordingly, in the first aspect, this invention provides a pharmaceutical
composition comprising a compound according to Formula I and a
pharmaceutically
acceptable carrier, diluent or excipient.
In still another aspect, this invention provides a method of treating diseases
in
which the disease pathology may be therapeutically modified by inhibiting NF-
xB.
In a particular aspect, this invention provides methods for treating a variety
of
diseases associated with NF-xB activation including inflammatory disorders;
particularly
rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis,
including
psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ
rejection; Alzheimer's
disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkins
disease; and certain
viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia
Telangiestasia.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a method of treatment of diseases associated
with
NF-xB activation, comprising administering to an animal, particularly a
mammal, most
particularly a human in need thereof a compound of Formula I:
0
~ ~ J/ ~ ''~'R1
N
R2/ \R3
wherein:
Rl is aryl;
R2 is selected from the group consisting of: H, C 1_6alkyl and aryl;
R3 is selected from the group consisting of: Cl_6alkyl and C3_g cycloalkyl;
and
R2 and R3 may be joined together to foam a heterocyclic ring of 5-7 atoms
selected from the group consisting of: C, N, O and S
and pharmaceutically acceptable salts, hydrates and solvates thereof.
The present invention particularly provides methods for treating inflammatory
disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and
asthma;
4
CA 02335293 2000-12-15
WO 99/65495 PCT/US99/13897
dermatosis, including psoriasis and atopic dermatitis; autoimmune diseases;
tissue and organ
rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer,
including Hodgkins
disease: and certain viral infections, including AIDS; osteoarthritis;
osteoporosis; and Ataxia
Telangiestasia.
Compounds of Formula I selected from the following group are preferred for use
in
the methods of the present invention:
3-[(N-Butyl)amino]-2-benzalindanone;
3-[(N-cyclohexyl)amino]-2-benzalindanone;
3-Morpholinyl-2-benzalindanone; and
3-Piperidinyl-2-benzalindanone.
Definitions
The present invention includes the use of all hydrates, solvates, complexes
and
prodtuos of the compounds of this invention. Prodrugs are any covalently
bonded
compounds which release the active parent drug according to Formula I in vivo.
If a chiral
center or another form of an isomeric center is present in a compound of the
present
invention. all forms of such isomer or isomers, including enantiomers and
diastereomers,
are intended to be covered herein. Compounds containing a chiral center may be
used as a
racemic mixture, an enantiomerically enriched mixture, or the racemic mixture
may be
separated using well-known techniques and an individual enantiomer may be used
alone.
In cases in which compounds have unsaturated carbon-carbon double bonds, both
the cis
(Z) and trans (E) isomers are within the scope of this invention. In cases
wherein
compounds may exist in tautomeric forms, such as keto-enol tautomers, each
tautomeric
form is contemplated as being included within this invention whether existing
in
equilibrium or predominantly in one form.
The meaning of any substituent at any one occurrence in Formula I or any
subformula thereof is independent of its meaning, or any other substituent's
meaning, at any
other occurrence, unless specified otherwise.
"C 1 _6alkyl" as applied herein is meant to include substituted and
unsubstituted
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and t-butyl, pentyl, n-
pentyl, isopentyl,
neopentyl and hexyl and the simple aliphatic isomers thereof. Any Cl_6alkyl
group may be
optionally substituted independently by one or two halogens, SR', OR', N(R~2,
C(OjN(R~~,
carbamyl or C 1 _4alkyl, where R' is C 1 _6alkyl.
5
CA 02335293 2000-12-15
WO 99/65495 PCT/US99/13897
"C3_g cycloalkyl" as applied herein is meant to include substituted and
unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
and cyciooctyl
and the simple aliphatic isomers thereof. Any C3_g cycloalkyl group may be
optionally
substituted independently by one or two halogens, SR', OR', N(R~2, C(O)N(R~2,
carbamyl
or C 1 _4alkyl, where R' is C 1 _6alkyl.
"Halogen" means F, Cl, Br, and I.
"Ar" or "aryl" means phenyl or naphthyl, optionally independently substituted
by
one or more of Ph-Cp_6alkyl, Het-Cp_6alkyl, C 1 _6alkyl, C 1 _6alkoxy, Ph-
Cp_6alkoxy, Het-
Cp_6alkoxy, OH, CN, C02R', or halogen. Cpalkyl means that no alkyl group is
present in
the moiety. Thus, Ar-Cpalkyl is equivalent to Ar. Two C 1 _6alkyl groups may
be combined
to form a 5-7 membered ring, saturated or unsaturated, fused onto the Ar ring.
Ph may be
optionally substituted with one or more of C I _6alkyl, C 1 _6alkoxy, OH,
C02R', or halogen.
As used herein "Het" or "heterocyclic" represents a stable 5- to 7-membered
monocyclic ring, which is either saturated or unsaturated, and which consists
of carbon
atoms and from one to three heteroatoms selected from the group consisting of
N, O and S,
and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized,
and the
nitrogen heteroatom may optionally be quaternized, and including any bicyclic
group in
which any of the above-defined heterocyclic rings is fused to a benzene ring.
The
heterocyclic ring may be attached at any heteroatom or carbon atom which
results in the
creation of a stable structure, and may optionally be substituted with one or
two moieties
selected from the group consisting of Ph-Cp_6alkyl, Het-Cp_6 alkyl, Cl_6alkyl,
C 1 _6alkoxy, Ph-Cp_6alkoxy, Het-Cp_6alkoxy, OH, or CN. Two C 1 _6alkyl groups
may be
combined to form a 5-7 membered ring, saturated or unsaturated, fused onto the
Het ring.
Ph may be optionally substituted with one or more of C 1 _6alkyl, C 1
_6aikoxy, OH, COZR',
or halogen. Examples of such heterocycles include the piperidinyl,
piperazinyl, 2-
oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl,
pyrrolyl, 4-
piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyI, imidazolyl, pyridyl,
pyrazinyl,
oxazolidinyl, oxazolinyl, oxazolyl, isoxazolyl, morpholinyl, thiazolidinyl,
thiazolinyl,
thiazolyl, quinuclidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl,
benzopyranyl,
benzoxazolyl, furyl, pyranyl, tetrahydrofuryl, tetrahydropyranyl, thienyl,
benzoxazolyl,
thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl rings.
6
CA 02335293 2000-12-15
- WO 99/65495 PC'T/IJS99/13897
Methods of Preparation
The compounds used in the methods of the present invention may be conveniently
prepared by the methods set forth in Scheme 1 below.
General preparation of amino indanone analogs was described by G. Maury, E.-M.
Wu, N. H. Cromwell, J. Org. Chem. 1968, 33, 1900-1907. The synthesis of the 3-
bromo
intermediate was described by B. D. Pearson, R. P. Ayer, N. H. Cromwell, J.
Org. Chem.
1962, 27, 3038-3044. The synthesis of 2-benzalindanone was desbribed by A.
Hassner, N.
H. Cromwell, J. Org. Chem i 958, 80, 893-900.
General Preparation:
The general preparation is shown in Scheme 1. An indanone is treated with a
benzylaldehyde in base to give a 2-benzalindanone. Bromination of a 2-
benzalindanone
with NBS in CCI, gives a 3-bromo-2-benzalindanone. Treatment of a 3-bromo-2-
benzalindanone with an alkyl primary or secondary amine in benzene gives a 3-
alkylamino-
2-benzalindanone.
Scheme 1
0 0 0
.. R,CHO - v NBS ' W ~.
Rt _ ~ ~ R7
Br
% R,R,NH
O
.. . ',Rt
i.
~N ~ R3
R2
Referring to the methods of preparing the compounds of Formula I set forth in
Schemes 1 above, the skilled artisan will appreciate that the present
invention includes all
novel intermediates required to make the compounds of Formula I.
7
CA 02335293 2000-12-15
WO 99/65495 PCT/US99/13897
The starting materials used herein are commercially available or are prepared
by
routine methods well known to those of ordinary skill in the art and can be
found in
standard reference books, such as the COMPENDIUM OF ORGANIC SYNTHETIC
METHODS. Vol. I-VI (published by Wiley-Interscience).
Acid addition salts of the compounds of Formula I are prepared in a standard
manner in a suitable solvent from the parent compound and an excess of an
acid, such as
hydrochloric, hydrobromic, hydrofluoric, sulfuric, phosphoric, acetic,
trifluoroacetic,
malefic, succinic or methanesulfonic. Certain of the compounds form inner
salts or
zwitterions which may be acceptable. Cationic salts are prepared by treating
the parent
compound with an excess of an alkaline reagent, such as a hydroxide, carbonate
or
alkoxide, containing the appropriate cation; or with an appropriate organic
amine. Cations
such as Li+, Na+, K+, Ca++, Mg++ and NH4+ are specific examples of cations
present in
pharmaceutically acceptable salts. Halides, sulfate, phosphate, alkanoates
(such as acetate
and trifluoroacetate), benzoates, and sulfonates (such as mesylate) are
examples of anions
present in pharmaceutically acceptable salts.
This invention provides a pharmaceutical composition which comprises a
compound according to Formula I and a pharmaceutically acceptable carrier,
diluent or
excipient. Accordingly, the compounds of Formula I may be used in the
manufacture of a
medicament. Pharmaceutical compositions of the compounds of Formula I prepared
as
hereinbefore described may be formulated as solutions or lyophilized powders
for
parenteral administration. Powders may be reconstituted by addition of a
suitable diluent
or other pharmaceutically acceptable carrier prior to use. The liquid
formulation may be a
buffered, isotonic, aqueous solution. Examples of suitable diluents are normal
isotonic
saline solution, standard 5% dextrose in water or buffered sodium or ammonium
acetate
solution. Such formulation is especially suitable for parenteral
administration, but may also
be used for oral administration or contained in a metered dose inhaler or
nebulizer for
insufflation. It may be desirable to add excipients such as
polyvinylpyrrolidone, gelatin,
hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or
sodium
citrate.
Alternately, these compounds may be encapsulated, tableted or prepared in an
emulsion or syrup for oral administration. Pharmaceutically acceptable solid
or liquid
carriers may be added to enhance or stabilize the composition, or to
facilitate preparation of
the composition. Solid carriers include starch, lactose, calcium sulfate
dihydrate, terra albs,
8
CA 02335293 2000-12-15
WO 99/65495 PCT/US99/13897
magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin.
Liquid carriers
include syrup, peanut oil, olive oil, saline and water. The carrier may also
include a
sustained release material such as glyceryl monostearate or glyceryl
distearate, alone or
with a wax. The amount of solid carrier varies but, preferably, will be
between about 20
mg to about I g per dosage unit. The pharmaceutical preparations are made.
following the
conventional techniques of pharmacy involving milling, mixing, granulating,
and
compressing, when necessary, for tablet forms; or milling, mixing and filling
for hard
geiatin capsule forms. When a liquid carrier is used, the preparation will be
in the form of
a syrup, elixir, emulsion or an aqueous or non-aqueous suspension. Such a
liquid
formulation may be administered directly p.o. or filled into a soft gelatin
capsule.
For rectal administration, the compounds of Formula I may also be combined
with
excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and
molded into a
suppository.
The methods of the present invention include topical administration of the
compounds of Formula I. By topical administration is meant non-systemic
administration,
including the application of a compound of the invention externally to the
epidermis, to the
buccal cavity and instillation of such a compound into the ear, eye and nose,
wherein the
compound does not significantly enter the blood stream. By systemic
administration is
meant oral, intravenous. intraperitoneal and intramuscular administration. The
amount of a
compound of Formula I (hereinafter referred to as the active ingredient)
required for
therapeutic or prophylactic effect upon topical administration will, of
course, vary with the
compound chosen, the nature and severity of the condition being treated and
the animal
undergoing treatment. and is ultimately at the discretion of the physician.
While it is possible for an active ingredient to be administered alone as the
raw
chemical, it is preferable to present it as a pharmaceutical formulation. The
active
ingredient may comprise, for topical administration, from 0.01 to 5.0 wt~7o.of
the
formulation.
The topical formulations of the present invention, both for veterinary and for
human medical use, comprise an active ingredient together with one or more
acceptable
carriers therefor, and optionally any other therapeutic ingredients. The
carrier must be
"acceptable" in the sense of being compatible with the other ingredients of
the formulation
and not deleterious to the recipient thereof.
9
CA 02335293 2000-12-15
WO 99/65495 PCT/US99/13897
Formulations suitable for topical administration include liquid or semi-liquid
preparations suitable for penetration through the skin to the site of where
treatment is
required such as: liniments, lotions, creams, ointments or pastes, and drops
suitable for
administration to the eye, ear or nose.
Drops according to the present invention may comprise sterile aqueous or oily
solutions or suspensions and may be prepared by dissolving the active
ingredient in a
suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any
other suitable
preservative, and preferably including a surface active agent. The resulting
solution may
then be clarified by filtration, transferred to a suitable container which is
then sealed and
sterilized by autoclaving or maintaining at 90-100 C for half an hour.
Alternatively, the
solution may be sterilized by filtration and transferred to the container by
an aseptic
technique. Examples of bactericidal and fungicidal agents suitable for
inclusion in the
drops are phenylmercuric nitrate or acetate (0.00290, benzalkonium chloride
(0.0190) and
chlorhexidine acetate (0.0190). Suitable solvents for the preparation of an
oily solution
include glycerol, diluted alcohol and propylene glycol.
Lotions according to the present invention include those suitable for
application to
the skin or eye. An eye lotion may comprise a sterile aqueous solution
optionally
containing a bactericide and may be prepared by methods similar to those for
the
preparation of drops. Lotions or liniments for application to the skin may
also include an
agent to hasten drying and to cool the skin, such as an alcohol or acetone,
and/or a
moisturizer such as glycerol or an oil such as castor oil or arachis oil.
Creams, ointments or pastes according to the present invention are semi-solid
formulations of the active ingredient for external application. They may be
made by
mixing the active ingredient in finely-divided or powdered form, alone or in
solution or
suspension in an aqueous or non-aqueous fluid, with the aid of suitable
machinery, with a
greasy or non-greasy basis. The basis may comprise hydrocarbons such as hard,
soft or
liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage: an oil of
natural origin such
as almond, corn, arachis, castor or olive oil; wool fat or its derivatives, or
a fatty acid such
as stearic or oleic acid together with an alcohol such as propylene glycol or
macrogols. The
formulation may incorporate any suitable surface active agent such as an
anionic, cationic
or non-ionic surface active agent such as sorbitan esters or polyoxyethylene
derivatives
thereof. Suspending agents such as natural gums, cellulose derivatives or
inorganic
CA 02335293 2000-12-15
WO 99/65495 PCT/US99/13897
materials such as silicaceous silicas, and other ingredients such as lanolin,
may also be
included.
Utility of the Present Invention
The compounds of Formula I are useful as inhibitors of NF-xB. The present
invention provides useful compositions and formulations of said compounds,
including
pharmaceutical compositions and formulations of said compounds.
The present invention also provides methods of treatment of diseases
associated
with NF-xB activation, which methods comprise administering to an animal,
particularly a
mammal, most particularly a human in need thereof a compound of Formula I. The
present
invention particularly provides methods for treating inflammatory disorders;
particularly
rheumatoid arthritis, inflammatory bowel disease, and asthma: dermatosis,
including
psoriasis and atopic dermatitis: autoimmune diseases; tissue and organ
rejection; Alzheimer's
disease: stroke; atherosclerosis: restenosis; cancer, including Hodgkins
disease; and certain
viral infections, including AIDS: osteoarthritis; osteoporosis: and Ataxia
Telangiestasia.
For acute therapy, parenteral administration of a compound of Formula I is
preferred. An intravenous infusion of the compound in 5~1c dextrose in water
or normal
saline, or a similar formulation with suitable excipients, is most effective,
although an
intramuscular bolus injection is also useful. Typically, the parenteral dose
will be about
0.01 to about 50 mg/kg; preferably between 0.1 and 20 mg/kg, in a manner to
maintain the
concentration of drug in the plasma at a concentration effective to inhibit
activation of NF-
xB. The compounds are administered one to four times daily at a level to
achieve a total
daily dose of about 0.4 to about 80 mg/kg/day. The precise amount of an
inventive
compound which is therapeutically effective, and the route by which such
compound is best
administered, is readily determined by one of ordinary skill in the art by
comparing the
blood level of the agent to the concentration required to have a therapeutic
effect.
The compounds of Formula I may also be administered orally to the patient, in
a
manner such that the concentration of drug is sufficient to inhibit NF-xB or
to achieve any
other therapeutic indication as disclosed herein. Typically, a pharmaceutical
composition
containing the compound is administered at an oral dose of between about 0.1
to about 50
mg/kg in a manner consistent with the condition of the patient. Preferably the
oral dose
would be about 0.5 to about 20 mg/kg.
11
CA 02335293 2000-12-15
WO 99/b5495 PCT/US99/13897
The compounds of Formula I may also be administered topically to the patient,
in a
manner such that the concentration of drug is sufficient to inhibit NF-KB or
to achieve any
other therapeutic indication as disclosed herein. Typically, a pharmaceutical
composition
containing the compound is administered in a topical formulation of between
about 0.01 %
to about 5% w/w.
No unacceptable toxicological effects are expected when compounds of the
present
invention are administered in accordance with the present invention.
The ability of the compounds described herein to inhibit the activation of NF-
tcB is
clearly evidenced in their ability to inibit NF-tcB-driven reporter gene
activity (see Table
1 ). The utility of the present NF-xB inhibitors in the therapy of diseases is
premised on the
importance of NF-xB activation in a variety of diseases.
12
CA 02335293 2000-12-15
- WO 99165495 PCT/ITS99/13897
Table 1
Inhibition of NF-xB-driven Reporter Gene Activity
O
- ~~~--'~''v
%,' ; -
Z
R
Compound R Reporter Assay
Number IC50
uM
1 N- ' 2.2. 1.0
H
I .7
N.~,~-
H
3 -N 1.9
4 N o 3.0
1490 C~ 5 uM
inactive
NF-xB plays a key role in the regulated expression of a large number of pro-
inflammatory mediators including cytokines such as IL-6 and IL-8 (Mukaida et
al., 1990;
Liberman and Baltimore, 1990; Matsusaka et al., 1993), cell adhesion
molecules, such as
ICAM and VCAM (Marui et al., 1993; ICawai et al., 1995; Ledebur and Parks,
1995), and
inducible nitric oxide synthase (iNOS) (Xie et al., 1994; Adcock et al.,
1994). (Full
reference citations are at the end of this section). Such mediators are known
to play a role
in the recruitment of leukocytes at sites of inflammation and in the case of
iNOS, may lead
13
CA 02335293 2000-12-15
WO 99/65495 PCT/tTS99/13897
to organ destruction in some inflammatory and autoimmune diseases (McCartney-
Francis
et al., 1993; Kleemann et al., 1993). Importantly, the compounds described
herein inhibit
IL-8 synthesis and the production of nitric oxide, a product of iNOS activity
(see Table 2).
TABLE 2
Anti-inflammatory Activity of Compound 2 in Table 1
In vitro
IL-1-induced PGE2 productionICSp = 1 uM
in RSF
ht vivo
Phorbol-ester-induced ear
inflammation
Ear swelling 85% inhibition @ 1 mg/ear
Inflammatory cell infiltration29% inhbiition @ 1 mg/ear
Evidence for an important role of NF-xB in inflammatory disorders is obtained
in
studies of asthmatic patients. Bronchial biopsies taken from mild atopic
asthmatics show
significant increases in the number of cells in the submucosa staining for
activated NF-xB,
total NF-xB, and NF-xB-regulated cytokines such as GM-CSF and TNFa compared to
biopsies from normal non-atopic controls (Wilson et al.. 1998). Furthermore,
the
percentage of vessels expressing NF-xB immunoreactivity is increased as is IL-
8
immunoreactivity in the epithelium of the biopsy specimens (Wilson et al.,
1998). As such,
inhibition of IL-8 production through the inhibition of NF-tcB, as has been
demonstrated by
these compounds would be predicted be beneficial in airway inflammation.
Recent studies suggest that NF-tcB may also play a critical rote in the
pathogenesis
of inflammatory bowel disease (IBD). Activated NF-tcB is seen in colonic
biopsy
specimens from Chron's disease and ulcerative colitis patients (Ardite et al.,
1998; Rogler
et al., 1998; Schreiber et al., 1998). Activation is evident in the inflamed
mucosa but not in
uninflamed mucosa (Ardite et al., 1998; Rogler et al., 1998) and is associated
with
increased IL-8 mRNA expression in the same sites (Ardite et al., 1998).
Furthermore,
corticosteroid treatment strongly inhibits intestinal NF-tcB activation and
reduces colonic
14
CA 02335293 2000-12-15
- WO 99/b5495 PCT/US99/I3897
inflammation (Ardite et al., 1998; Schreiber et al., 1998). Again, inhibition
of IL-8
production through the inhibition of NF-xB, as has been demonstrated by these
compounds
would be predicted be beneficial in inflammatory bowel disease.
Animal models of gastrointestinal inflammation provide further support for NF-
xB
as a key regulator of colonic inflammation. Increased NF-xB activity is
observed in the
lamina propria macrophages in 2,4,6,-trinitrobenzene sulfonic acid (TNBS)-
induced colitis
in mice with p65 being a major component of the activated complexes (Neurath
et al.,
1996; Neurath and Pettersson, 1997). Local administration of p65 antisense
abrogates the
signs of established colitis in the treated animals with no signs of toxicity
(Neurath et al.,
1996; Neurath and Pettersson, 1997). As such. one would predict that small
molecule
inhibitors of NF-xB would be useful in the treatment of IBD.
Further evidence for a role of NF-xB in inflammatory disorders comes from
studies
of rheumatoid synovium. Although NF-xB is normally present as an inactive
cytoplasmic
complex, recent immunohistochemical studies have indicated that NF-xB is
present in the
nuclei, and hence active, in the cells comprising human rheumatoid synovium
(Handel et
al., 1995; Marok et al., 1996: Sioud et al., 1998) and in animal models of the
disease (Tsao
et al., 1997). The staining is associated with type A synoviocytes and
vascular endothelium
(Marok et al., 1996). Furthermore, constitutive activation of NF-xB is seen in
cultured
synoviocytes (Roshak et al., 1996; Miyazawa er al., 1998) and in synovial cell
cultures
stimulated with IL-1 (3 or TNFa (Roshak et al., 1996: Fujisawa et al., 1996;
Roshak et al.,
1997). Thus, the activation of NF-xB may underlie the increased cytokine
production and
leukocyte infiltration characteristic of inflamed synovium. The ability of
these compounds
to inhibit NF-xB and thereby inhibit the production of eicosanoids by these
cells would be
predicted to yield benefit in rheumatoid arthritis (see Table 2).
CA 02335293 2000-12-15
- WO 99/65495 PCT/US99/13897
Mukaida N, MaheY, Matsushima K ( 1990) Cooperative interaction of nuclear
factor-xB-
and cis-regulatory enhancer binding protein-like factor binding elements in
activating
the interleukin-8 gene by pro-inflammatory cytokines. J Biol Chem 265: 21128-
21133
Liberman TA, Baltimore D ( 1990) Activation of interleukin-6 gene expression
through NF-
tcB transcription factor. Mol Cell Biol 10: 2327-2334
Matsusaka T, Fujikawa K, Nishio Y, Mukaida N, Matsushima K. Kishimoto T, Akira
S
( 1993) Transcription factors NF-IL6 and NF-xB synergistically activate
transcription of
the inflammatory cytokines interleukin 6 and interleukin 8. Proc Natl Acad Sci
USA 90:
10193-10197
Marui N, Offerman MK, Swerlick, R, Kunsch C, Rosen CA, Ahmad M, Alexander RW,
Medford RM (1993) Vascular cell adhesion molecule-1 (VCAM-1) gene
transcription
and expression are regulated through an antioxidant-sensitive mechanism in
human
vascular endothelial cells. J Clin Invest 92: 1866-1874
Kawai M, Nishikomori R, Jung E-Y, Tai G, Yamanak C, Mayumi M, Heike T ( 1995)
Pyrrolidine dithiocarbamate inhibits intercellular adhesion molecule-1
biosynthesis
induced by cytokines in human fibroblasts. J Immunol 154: 2333-2341
Ledebur HC, Parks TP ( 1995) Transcriptional regulation of the intracellular
adhesion
molecule-1 gene by inflammatory cytokines in human endothelial cells. J Biol
Chem
270: 933-943
Xie Q, Kashiwabara Y, Nathan C ( 1994) Role of transcription factor NF-xB/Rel
in
induction of nitric oxide synthase. J Biol Chem 269: 4705-4708
Adcock INi, Brown CR. Kwon O. Barnes PJ ( 1994) Oxidative stress induces NF-
tcB DNA
binding and inducible NOS mRNA in human epithelial cells. Biochem Biophys Res
Commun 199: 1518-1524
McCartney-Francis N, Allen JB, Mizel DE, Albina JE, Xie Q, Nathan CF, WahI SM
( 1993)
Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med
178: 749-
754
Kleemann R, Rothe H, Kolb-Bachofen V, Xie Q, Nathan C. Martin S, Kolb H (
1993)
Transcription and translation of inducible nitric oxide synthase in the
pancreas of
prediabetic BB rats. FEBS Lett 328: 9-12
Wilson SJ, Wallin A, Sandstrom T, Howarth PH, Holgate ST ( 1998) The
expression of NF-
kappa-B and associated adhesion molecules in mild asthmatics and normal
controls. J
Allergy Clin Immunol 101: 616
16
CA 02335293 2000-12-15
- WO 99165495 PCT/US99113897
Ardite E, Panes J, Miranda M, Salas A. Elizalde JI, Sans M, Arce Y, Bordas JM,
Fernandez-Checa JC, Pique JM ( 1998) Effects of steroid treatment on
activation of
nuclear factor xB in patients with inflammatory bowel disease. Br J Pharmacol
124:
431-433
S Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knuechel R,
Baeuerle PA,
Scholmerich J, Gross V ( 1998) Nuclear factor xB is activated in macrophage
and
epithelial cells of inflamed intestinal mucosa. Gastroenterol 115: 357-369
Schreiber S. Nikoiaus S, Hampe J ( 1998) Activation of nuclear factor xB in
inflammatory
bowel disease. Cut 42: 477-484
Neurath MF, Pettersson S, Meyer zum Buschenfelde K-H, Strober W ( 1996) Local
administration of antisense phosphorothioate oligonucleotides to the p65
subunit of
NF-xB abrogates established experimental colitis in mice. Nature Med 2: 998-
1004
Neurath MF. Pettersson S ( 1997) Predominant role of NF-xB p65 in the
pathogenesis of
chronic intestinal inflammation. Immutiobiol 198: 91-98
Handel ML. McMorrow LB, Gravailese EM ( 1995) Nuclear factor -xB in rheumatoid
synovium; localization of p50 and p65. Arthritis Rheumatism 38: 1762-1770
Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades S, Mapp PI, Morris
CJ,
Blake DR, Kaltschmidt C, Baeuerle PA ( 1996) Activation of the transcription
factor
nuclear factor-xB in human inflamed synovial tissue. Arthritis Rhetcmatism 39:
583-
591
Sioud M, Mellbye O, Forre O ( 1998) Analysis of the NF-xB p65 subunit, Fas
antigen. Fas
ligand and Bcl-2-related proteins in the synovium of RA and polyarticular JRA.
Clin
ExpRheumatol 16: 125- l34
Tsao PW, Suzuki T, Totsuka R, Murata T, Takagi T, Ohmachi Y, Fujimura H.
Takata I
( 1997) The effect of dexamethasone on the expression of activated NF-xB in
adjuvant
arthritis. Clin Immunol Immunopathol 83: 173-178
Roshak AK, Jackson JR, McGough K, Chabot-Fletcher M, Mochan E, Marshall L (
1996)
Manipulation of distinct NFxB proteins alters interleukin-1 j3-induced human
rheumatoid synovial fibroblast prostaglandin E2 formation. J Biol Chem 271:
31496-
31501
17
CA 02335293 2000-12-15
WO 99/65495 PGT/US99/13897
Miyazawa K, Mori A, Yamamoto K, Okudaira H ( 1998) Constitutive transcription
of the
human interleukin-6 gene by rheumatoid synoviocytes; spontaneous activation of
NF-
xB and CBFI . Am J Pathol 152, 793-803
Fujisawa K, Aono H, Hasunuma T, Yamamoto K, Mita S, Nishiola K ( 1996)
Activation of
transcription factor NF-xB in human synovial cells in response to tumor
necrosis factor
a. Arthritis Rheumatism 39: 197-203
Roshak AK, Jackson 1R, Chabot-Fletcher M, Marshall L ( 1997) Inhibition of
NFxB-
mediated interleukin-1 (i-stimulated prostaglandin E2 formation by the marine
natural
product hymenialdisine. J Pharmacol Exp Therapeut 283: 955-961
Biological Assays
The compounds of this invention may be tested in one of several biological
assays
to determine the concentration of compound which is required to have a given
pharmacological effect.
Assays of NF-xB activity are conducted using a cell based luciferase reporter
assay
as described in Breton, J. J and Chabot-Fletcher, M. C., JPET, 282, 459-466 (
1997).
Briefly, U937 human histiocytic lymphoma cell line permanently transfected
with the NF-
xB reporter plasmids (see below) are cultured in the above medium with the
addition of
250 ~tg/ml Geneticin (G418 sulfate, Life Technologies, Grand Island, NY). The
luciferase
reporter assay is conducted in the transfected U937 clones. These are twice
centrifuged at
300 xg for ~ min and resuspended in RPMI 1640 with 1090 FBS to a density of I
x 10°
cells/ml. One ml aliquots are added to the wells of 24-well plates. Compound
or dimethyi
sulfoxide (DMSO) carrier ( 1 Nl) is added to the appropriate wells and the
plates are
incubated at 37°C, 5~1o CO, for 30 min. The stimulus is added (5 ng/ml
TNFx, 100 ng/ml
LPS, or 0.1 ltM PMA) and the samples incubated for 5 hours at 37°C, 5%
CO" transferred
to 1.9 ml polypropylene tubes, and centrifuged at 200 xg for 5 min. The cell
pellets are
washed twice in 1 ml PBS without Ca-' and Mg'', and centrifuged as indicated
above. The
resulting cell pellets are lysed in 50 Nl lx lysis buffer (Promega
Corporation, Madison, WI),
vortexed and incubated for 15 min at room temperature. A 20 pl aliquot of each
lysate is
transferred to an opaque white 96-well plate (Wallac Inc., Gaithersburg, MD)
and assayed
for luciferase production in a MicroLumat LB 96 P luminometer (EG&G Berthold,
Bad
Wilbad, Germany). The luminometer dispenses 100 pl luciferase assay reagent
(Promega
18
CA 02335293 2000-12-15
WO 99/65495 PCT/US99/13897
Corporation, Madison, WI) into each well and the integrated light output is
recorded for 20
sec. Light output is measured in relative light units (RLUs).
NF-xB activity may also be measured in an electrophoretic mobility shift assay
(EMSA) to assess the presence of NF-xB protein in the nucleus. The cells of
interest are
cultured to a density of l x 10" /ml. The cells are harvested by
centrifugation, washed in
PBS without Ca~' and Mg'' and resuspended in PBS with Ca-' and Mg-' at 1 x 10'
cells/ml.
To examine the effect of compound on the activation of NF-xB, the cell
suspensions are
treated with various concentrations of drug or vehicle (DMSO, 0.1 %) for 30
min at 37°C
prior to stimulation with TNFa (S.Ong/ml) for an additional 1 S min. Cellular
and nuclear
extracts are prepared follows Briefly, at the end of the incubation period the
cells ( 1 x 10'
cells) are washed 2x in PBS without Ca'' and Mg''. The resulting cell pellets
are
resuspended in 20 pl of Buffer A ( l OmM Hepes (pH 7.9), 1 OmM KCI, 1.SmM
MgCI"
O.SmM dithiothreitol (DTT) and 0.1 % NP-40) and incubated on ice for l0 min.
The nuclei
are pelleted by microcentrifugation at 3500 rpm for 10 min at 4°C. The
resulting
supernatant was collected as the cellular extract and the nuclear pellet was
resuspended in
15 lzl Buffer C (20mM Hepes (pH 7.9), 0.42M NaCI, I.SmM MgCI,. 25% glycerol,
0.2mM
EDTA, 0.5mM DTT, and O.SmM phenylmethylsulphonyl fluoride (PMSF)). The .
suspensions are mixed gently for 20 min at 4°C then microcentrifuged at
14,000 rpm for 10
min at 4°C. The supernatant is collected and diluted to 60 pl with
Buffer D (20mM Hepes
(pH 7.9), SOmM KCI, 20% glycerol, 0.2mM EDTA, 0.5rnM DTT, and 0.5mM PMSF). All
samples are stored at -80°C until analyzed. The protein concentration
of the extracts is
determined according to the method of Bradford (Bradford. 1976) with BioRad
reagents.
The effect of compounds on transcription factor activation is assessed in an
electrophoretic mobility shift assay (EMSA) using nuclear extracts from
treated cells as
described above. The double stranded NF-xB consensus oligonucleotides (S'-
AGTTGAGGGGACTTTCCCAGGC-3') are labelled with Tj polynucleotide kinase and [g-
'ZP]ATP. The binding mixture (25 pl) contains IOmM Hepes-NaOH (pH 7.9), 4mM
Tris-
HCl (pH 7.9), 60mM KCI, 1 mM EDTA, 1 mM dithiothreitol. 10% glycerol, 0.3
mg/ml
bovine serum albumin, and 1 pg poly(dI-dC)~poly(dI-dC). The binding mixtures (
10 ~tg
nuclear extract protein) are incubated for 20 min at room temperature with 0.5
ng of''P-
labelled oligonucleotide (50,000-100,000 cpm) in the presence or absence of
unlabeled
competitor after which the mixture is loaded on a 4% polyacrylamide gel
prepared in 1X
19
CA 02335293 2000-12-15
WO 99/65495 PCT/US99/13897
Tris borate/EDTA and electrophoresed at 200 V for 2 h. Following
electrophoresis the
gels are dried and exposed to film for detection of the binding reaction.
The effect of compounds on the phosphorylation of hcB may be monitored in a
Western blot. Cellular extracts are subjected to sodium dodecyl sulfate-
polyacryiamide gel
electrophoresis (SDS-PAGE) on 10% gels (BioRad, Hercules, CA) and the proteins
transferred to nitrocellulose sheets (Hybond'"'-ECL, Amersham Corp., Arlington
Heights,
IL). Immunoblot assays are performed using a polyclonal rabbit antibody
directed against
IxBa or IxB~i followed with a peroxidase-conjugated donkey anti-rabbit
secondary
antibody (Amersham Corp., Arlington Heights, IL). Immunoreactive bands are
detected
using the Enchanced Chemiluminescence (ECL) assay system (Amersham Corp.,
Arlington
Heights, IL).
Effects on eicosanoid production by human synovial fibroblasts (RSF) are
assessed
using primary cultures of human RSF. These are obtained by enzymatic digestion
of
synovium obtained from adult patients with rheumatoid. Cells are cultured in
Earl's
Minimal Essential Medium (EMEM) containing 10% fetal bovine serum (FBS), 100
units/ml penicillin and 100 pg/ml streptomycin (GIBCO, Grand Island, NY), at
37°C and
5% C02, Cultures are used at passages 4 through 9 in order to obtain a more
uniform type
I fibroblast population. For some studies, fibroblasts are plated at 5 x 104
cells/ml in
l6mm (diameter) 24 well plates (Costar, Cambridge, MA). Cells are exposed to
an optimal
dose of IL-113 ( 1 ng/ml; Roshak et al. 1996a)(Genzyme, Cambridge, MA) for the
designated
time. Drugs in DMSO vehicle ( 1 %) are added to the cell cultures 15 minutes
prior to the
addition of IL-1. Prostaglandin E2 levels in cell-free medium collected at the
termination of
the culture period are directly measured using enzyme immunoassay (EIA) kits
purchased
from Cayman Chemical Co. (Ann Arbor, MI). Sample or standard dilutions are
made with
experimental medium.
Anti-inflammatory activity in vivo is assessed using the phorbol ester-induced
ear
inflammation model in mice. Phorboi myristate acetate (PMA) (4p.g/20111
acetone) is
applied to the inner and outer surfaces of the left ear of Male Balb/c mice
(6/group)
(Charles River Breeding Laboratories, Wilmington, MA). Four hours later,
compound
dissolved in 2511 acetone is applied to the same ear. The thickness of both
ears is
measured with a dial micrometer (Mitutoyo, Japan) after 20 hours and a second
topical
dose of compound is applied. Twenty-four hours later, ear thickness
measurements are
taken and the data expressed as the change in thickness (x 10-3cm) between
treated and
CA 02335293 2000-12-15
- WO 99/65495 PCT/US99/13897
untreated ears. The inflamed left ears are then removed and stored at -
70°until assayed for
myeloperoxidase (MPO) activity, a measure of inflammatory cell infiltration.
Inflammatory cell infiltration is assessed through the measurement of
myeloperoxidase activity present in the inflammed ear tissue. Partially thawed
ear tissues
are minced and then homogenized ( 10% w/v) with a Tissumizer homogenizes
(Tekmar Co.,
Cincinnati, OH) in SO mM phosphate buffer (pH 6) containing 0.5% HTAB. The
tissue
homogenates are taken through three cycles of freeze-thaw, followed by brief
sonication
( lOs). MPO activity in the homogenates is determined as follows. The
appearance of
colored product from the MPO-dependent reaction of o-dianisidine (0.167 mg/ml,
Sigma
Chemical. St. Louis, MO) and hydrogen peroxide (0.0005%) is measured
spectrophotometrically at 460 nm. Supernatant MPO activity is quantified
kinetically
(change in absorbance measured over 3 min, sampled at I S s intervals) using a
Beckman
DU-7 spectrophotometer and a kinetics analysis package (Beckman Instruments,
Inc.,
Sommerset, NJ). One unit of MPO activity is defined as that degrading one
micromole of
peroxide per minute at 25°C.
Effects on inflammation-mediated cartilage breakdown is measured in an in
vitro
cartilage explant system. In this model bovine articular cartilage explants
are incubated for
4 days/96 hours with or without rHuIL-1 alpha to stimulate cartilage breakdown
in the
presence or absence of test compound. The supernatants are removed for the
nitric oxide
assays. Nitric oxide was measured using the Greiss reaction and read
spectrophotometricaliy at 530nm. This reaction measures nitrite (N02) which is
the stable
end product of nitric oxide.
General
Nuclear magnetic resonance spectra were recorded at either 250, 300 or 400 MHz
using, respectively, a Bruker AM 250, Bruker, Bruker ARX 300 or Bruker AC 400
spectrometer. CDCl3 is deuteriochloroform, DMSO-d6 is
hexadeuteriodimethylsulfoxide,
and CD30D is tetradeuteriomethanoi. Chemical shifts are reported in parts per
million (d)
downfield from the internal standard tetramethylsilane. Abbreviations for NMR
data are as
follows: s = singles, d = doublet, t = triplet, q = quartet, m = multiplet, dd
= doublet of
doublets, dt = doublet of triplets, app = apparent, br = broad. J indicates
the NMR coupling
constant measured in Hertz. Continuous wave infrared (IR) spectra were
recorded on a
21
CA 02335293 2000-12-15
WO 99/65495 PCT/US99/13897
Perkin-Elmer 683 infrared spectrometer, and Fourier transform infrared (FTIR)
spectra
were recorded on a Nicolet Impact 400 D infrared spectrometer. IR and FTIR
spectra were
recorded in transmission mode, and band positions are reported in inverse
wavenumbers
(cm-1). Mass spectra were taken on either VG 70 FE, PE Syx API III, or VG ZAB
HF
S instruments, using fast atom bombardment (FAB) or electrospray (ES)
ionization
techniques. Elemental analyses were obtained using a Perkin-Elmer 240C
elemental
analyzer. Melting points were taken on a Thomas-Hoover melting point apparatus
and are
uncorrected. All temperatures are reported in degrees Celsius.
Analtech Silica Gel GF and E. Merck Silica Gel 60 F-254 thin layer plates were
used for thin layer chromatography. Both flash and gravity chromatography were
carried
out on E. Merck Kieselgel 60 (230-400 mesh) silica gel.
Where indicated, certain of the materials were purchased from the Aldrich
Chemical Co.. Milwaukee, Wisconsin.
Examples
In the following synthetic examples, temperature is in degrees Centigrade
(°C).
Unless otherwise indicated, all of the starting materials were obtained from
commercial
sources. Without further elaboration, it is believed that one skilled in the
art can, using the
preceding description, utilize the present invention to its fullest extent.
These Examples are
given to illustrate the invention, not to limit its scope. Reference is made
to the claims for
what is reserved to the inventors hereunder.
Example 1
Preparation of 3-f(N-Buvt)aminol-2-benzalindanone
a) 2-Benzalindanone.
Following the procedure of A. Hassner, N. H. Cromwell, J. Org. Chem 1958, 80,
893-900, benzaldehyde (6.05 mL, 53.6 mmol) was added to a solution of indanone
(Aldrich, 7.08 g, 53.6 mmol) in ethanol and KOH {600 mg, 10.6 mmol) at 0 C and
the
reaction sat in the refrigerator overnight. The reaction mixture was filtered,
washed with
50% aqueous EtOH and then recrystallized from hot ethanol to give 5.84 g of 2-
22
CA 02335293 2000-12-15
WO 99/65495 PCT/US99/13897
benzalindanone. 1 H NMR (300 MHz, CDC13) 8 7.93( d, I H, J = 7.7), 7.75-7.35
(m, 8H),
4.08 (s, 2H).
b) 3-Bromo-2-benzaiindanone,
Following the procedure of B. D. Pearson, R. P. Ayer, N. H. Cromwell, J. Org.
Chem. 1962, 27, 3038-3044, compound ( 1.0 g, 4.55 mmol) from Example 1 (a) in
CC14 ( 15
mL) was treated with NBS (810 mg, 4.55 mmol) and benzoyl peroxide (50 mg) and
the
mixture heated at reflux with a heat lamp for 1 h. The reaction was cooled,
filtered and the
filtrate evaporated to give 3-bromo-2-benzalindanone which was used without
further
purification. 1H NMR (300 MHz, CDC13) 8 8.1- 7.2 (m, lOH), 6.40 (s, 2H).
c) 3-[(N-Buyl)amino]-2-benzalindanone
Following the procedure of G. Maury, E.-M. Wu. N. H. Cromwell, J. Org. Chem.
1968, 33, 1900-1907, compound from Example 1(b) in benzene was treated with n-
butylamine (300 uL, 3.04 mmol) and the solution stirred at RT for 24 h. The
reaction was
evaporated and the residue purified by flash chromatography (silica gel,
10°lo ethyl acetate
in hexane) to give 353 mg of 3-[(N-butyl)amino)-2-benzalindanone. A portion of
the free
base in ether was treated with 1N HCI in ether to give the hydrochloride salt
as a solid. ES-
MS (M+H)+ m/e 292; 1H NMR (300 MHz, CDCl3) X8.2 (d, 1 H, J = 7.0 Hz), 8.03 (s,
1H),
7.98 (d, 1 H, J = 6 Hz), 7.84 (t, 1H, J = 6 Hz), 7.75- 7.50 (m, 7H), 6.7 (br
s, lH)2.48 (br
sIH), 2.28 (br s, 1H). 1.6-1.3 (m, 2H), 0.95-0.8 (m, 2H), 0.65 (t, 3H, J=6.5
Hz).
The above specif;cation and Example fully disclose how to make and use the
compounds of the present invention. However, the present invention is not
limited to the
particular embodiments described hereinabove, but includes all modifications
thereof
within the scope of the following claims. The various references to journals,
patents and
other publications which are cited herein comprise the state of the art and
are incorporated
herein by reference as though fully set forth.
23
